All HHS Contracts — October 09, 2026

Abbott's firm-fixed-price BARDA contract (awarded 2022-09-21) carries $65,469,510 obligated against an $83,713,826 base-plus-options value, with only $17,555,624 outlayed. A future FDA marketing application for the expanded TBI indication could convert this R&D funding into a commercial pathway, though no FDA approval is stated in the data.

Only about 24% of the $191,938,367 base-plus-options ceiling is obligated, and roughly 45% of the current obligation ($20,340,851) has been outlayed, leaving the majority of value contingent on option exercise. The contract is flagged high pricing risk and the recipient's listing status and revenue base are not disclosed.

The Time and Materials O&M contract for NIOSH sites has $12,377,735 outlayed against a $26,243,064 obligation, and T&M pricing shifts cost exposure toward the government while limiting margin visibility. The joint venture has no identified public parent, so the impact is confined to the private entity.

The delivery order's current end date of 2024-01-10 has passed as of this reference point with $17,329,680 obligated and only about $824,297 of ceiling remaining, with no extension or successor award shown. Without confirmation of recompete or extension, the revenue stream is not evidenced as recurring.

RELI Group's sole-source follow-on under the SPARC IDIQ provides incumbent continuity on NPPES O&M, and $10,930,650 of the $12,859,897 obligation has already been outlayed. The high outlay ratio means the revenue is largely recognized, so the signal reflects continuity rather than new pipeline.

VERSA's 8(a) competed delivery order for the Human Resource Enterprise System has $8,341,023 outlayed against an $11,773,314 obligation, with a potential ceiling of $19,622,021 if options are exercised through 2029. Company-level financials are not disclosed, so this remains a single-contract signal.

eMagine's firm-fixed-price order for CMS FISMA security and risk management has $9,982,873 obligated against a $40,084,019 base-plus-options value, with $4,952,437 outlayed and a potential end in 2031. The full-and-open competition with no set-aside means the win reflects general competition rather than protected status.

ATL's time-and-materials BPA call has $9,763,379 obligated against a $53,217,449 base-plus-options value, with about 18% of potential value funded and $3,140,446 outlayed. Future value depends on option exercises through 2031-03-16.

Across the set, most awards carry large unobligated option value (Basilea 24% obligated, CAS FSE 59%, ATL 18%, eMagine 25%), so realized revenue depends on future appropriations and option exercise rather than the headline ceiling.

NTT DATA's CDC hosting order has passed its current end date with almost no ceiling left, and no extension or successor is shown in the data.

Abbott's TBI diagnostic expansion depends on a future FDA marketing application that is not yet confirmed, and the R&D funding does not guarantee a commercial product.

Multiple small-business and 8(a) recipients (CAS FSE, RELI, VERSA, eMagine, ATL) depend on set-aside eligibility, and changes to 8(a) status or size standards could affect future awards.

Abbott's TBI diagnostic has substantial unspent BARDA funding ($65.5M obligated vs $17.6M outlayed) that could expand into a commercial product if FDA clearance is secured.

RELI Group's sole-source NPPES follow-on positions it for continued CMS O&M work, with the contract ending 2026-11-29 and no options shown.

VERSA and eMagine hold the CMS HRES and FISMA work under small-business and 8(a) channels with potential values of $19.6M and $40.1M, creating extended option-driven upside.

Basilea's $191.9M BARDA ceiling for antibiotics against gram-negative bacteria offers significant upside if options are exercised.

CMS and CDC awards in this set are weighted toward O&M, application support, and compliance services (RELI NPPES, VERSA HRES, eMagine FISMA, NTT DATA hosting) rather than new platform development.

BARDA/ASPR awards to Abbott Laboratories ($65.5M) and Basilea Pharmaceutica ($45.2M) show continued federal investment in diagnostics and antibiotics, though value depends on option exercise and regulatory outcomes.

{"entity" => "Abbott Laboratories", "reason" => "Largest award in the set at $65,469,510 obligated, with a TBI diagnostic expansion pending FDA marketing review.", "trigger" => "FDA decision on expanded TBI indication and option exercise toward $83.7M"}

{"entity" => "Basilea Pharmaceutica International Ltd / Basilea Pharmaceutica AG", "reason" => "Only about 24% of the $191.9M ceiling is obligated; listing status and revenue base are not disclosed.", "trigger" => "Option exercise and any performance period extension to 2029-12-31"}

{"entity" => "RELI Group Inc", "reason" => "Sole-source follow-on with 85% already outlayed and a firm end date of 2026-11-29.", "trigger" => "Follow-on or recompete announcement before 2026-11-29"}

{"entity" => "NTT DATA Services Federal Government, LLC", "reason" => "Delivery order past its current end date with almost all ceiling used.", "trigger" => "Extension, modification, or successor recompete for CDC hosting"}

{"entity" => "CMS IT services segment (VERSA, eMagine)", "reason" => "Ongoing CMS HRES and FISMA funding with long potential tails to 2029 and 2031.", "trigger" => "Option exercise around 2027-02-05 and 2027-06-21"}